Skip to main content

Linvoseltamab

Generic name: linvoseltamab [ LIN-voe-SEL-ta-mab ]
Brand name: Lynozyfic
Dosage form: intravenous solution (gcpt 2 mg/mL; gcpt 20 mg/mL)
Drug class: Bispecific T-cell engagers (BiTE)

Medically reviewed by Drugs.com on Aug 5, 2025. Written by Cerner Multum.

What is linvoseltamab?

Linvoseltamab is used to treat adults with multiple myeloma who have received at least 4 treatment regimens and their cancer has returned or did not respond to a previous treatment.

Linvoseltamab is available only under a special program. You must be registered in the program and understand the risks and benefits of linvoseltamab.

Linvoseltamab may also be used for purposes not listed in this medication guide.

Linvoseltamab side effects

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Tell your medical caregivers if you have signs of cytokine release syndrome (CRS), a serious side effect: fever, chills, trouble breathing, confusion, severe vomiting or diarrhea, fast or irregular heartbeats, feeling light-headed or very tired.

Some side effects may occur during the injection. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.

Linvoseltamab may cause serious side effects. Call your doctor at once if you have:

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of linvoseltamab may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings

Call your doctor if you have symptoms of neurological problems such as headache, agitation, tiredness, confusion, hallucinations, problems with thinking or memory, unusual muscle problems or pain, numbness and tingling, seizures, walking difficulties, handwriting or speech changes.

Tell your medical caregivers if you have symptoms of a serious side effect, such as fever, chills, trouble breathing, vomiting, or severe tiredness.

Before taking this medicine

Tell your doctor if you have or have ever had:

May harm an unborn baby. Do not use if you are pregnant. You may need a pregnancy test to make sure you are not pregnant. Use effective birth control while using linvoseltamab and for at least 3 months after your last dose. Tell your doctor if you become pregnant.

Do not breastfeed while using linvoseltamab, and for at least 3 months after your last dose.

How is linvoseltamab given?

Follow all directions on your prescription label and read all medication guides or instruction sheets.

Read the Patient Wallet Card about serious side effects and learn what symptoms to watch for. Keep the card with you at all times.

Linvoseltamab is given as an infusion into a vein by a healthcare provider.

You will need to stay in the hospital for 24 hours after some doses of linvoseltamab. Talk with your doctor if you have any questions.

Your doctor will determine the right treatment schedule for you.

You may be given other medications to help prevent serious side effects or allergic reaction. Keep using these medicines for as long as your doctor has prescribed. Your doctor will monitor you for these side effects.

You will need frequent medical tests and your cancer treatments may be delayed or discontinued based on the results.

Linvoseltamab dosing information

Usual Adult Dose for Multiple Myeloma:

Step-Up Dosing:
-Day 1 (step-up dose 1): 5 mg via IV infusion over 4 hours as a single dose
-Day 8 (step-up dose 2): 25 mg via IV infusion over 4 hours as a single dose
-Day 15 (first treatment dose): 200 mg via IV infusion over 4 hours as a single dose

Weekly Dosing:
-One week after Day 15 (second treatment dose): 200 mg via IV infusion over 1 hour as single dose
-Weeks 4 to 13: 200 mg via IV infusion over 30 minutes once a week (for a total of 10 treatment doses)

Biweekly Dosing:
-Week 14 and thereafter: 200 mg via IV infusion over 30 minutes every 2 weeks

Monthly Dosing:
-Week 24 or after: 200 mg via IV infusion over 30 minutes every 4 weeks only if a very good partial response (VGPR) or better is achieved/maintained at or after Week 24 AND after at least 17 doses of 200 mg.

Comments:
-Carefully review the dosing tables/recommendations in the manufacturer product information before administration.
-Administer as an IV infusion according to the step-up schedule to reduce the incidence/severity of cytokine release syndrome (CRS).
-For patients without CRS, the infusion duration can be reduced for subsequent doses as recommended by the manufacturer; for patients who experienced CRS with a previous dose, the infusion duration should be maintained at the duration of the previous infusion.
-Weekly doses should be given at least 5 days apart; biweekly doses should be at least 10 days apart; every 4-week doses should be at least 24 days apart.
-Pretreatment medications are recommended to reduce the risk of CRS and infusion-related reactions (IRR).
-Duration of therapy: Until disease progression or unacceptable toxicity.

Use: For the treatment of relapsed or refractory multiple myeloma in patients who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your linvoseltamab injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid while receiving linvoseltamab?

Avoid driving or hazardous activity for 48 hours after receiving certain doses of linvoseltamab or until neurological symptoms go away. Your reactions could be impaired.

What other drugs will affect linvoseltamab?

Other drugs may affect linvoseltamab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Does Linvoseltamab interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Linvoseltamab Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for linvoseltamab.

Lynozyfic (linvoseltamab-gcpt) - Regeneron Pharmaceuticals, Inc.
Formulation type Strength
Single-Dose Vial 200 mg/10 mL (20 mg/mL)
Single-Dose Vial 5 mg/2.5 mL (2 mg/mL)

View Lynozyfic information in detail.

More about linvoseltamab

Patient resources

Other brands

Lynozyfic

Professional resources

Other brands

Lynozyfic

Related treatment guides

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.